Latest news
Nippon Shinyaku (TSE:4516) Secures Tadekinig Alfa US Rights, Is The Valuation Gap Justified? - simplywall.stsimplywall.st · Thu, 06 Aug 2026 19:06:28 GMTAB2 Bio Receives $30 Million From Nippon Shinyaku For U.S. Tadekinig Alfa Rights, With Up To $600 Million In Milestones And Royalties - Pulse 2.0Pulse 2.0 · Mon, 03 Aug 2026 01:58:58 GMTNS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO's Tadekinig alfa in the U.S. - PR NewswirePR Newswire · Thu, 30 Jul 2026 13:03:00 GMTAB2 Bio gets $30M from Nippon Shinyaku for U.S. rights to Tadekinig alfa treating rare hyperinflammatory syndrome - PluangPluang · Thu, 30 Jul 2026 07:19:23 GMTAB2 Bio Gets $30 Mln From Nippon Shinyaku For U.S. Rights To Tadekinig Alfa - TradingViewTradingView · Thu, 30 Jul 2026 06:51:00 GMTAB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 06:37:58 GMT